ROYALTY PHARMA PLC- CL A (RPRX) Stock Price, Quote, News and Overview
NASDAQ:RPRX - Nasdaq - GB00BMVP7Y09 - Common Stock - Currency: USD
RPRX Quote, Performance and Key Statistics
ROYALTY PHARMA PLC- CL A
NASDAQ:RPRX (2/4/2025, 8:05:31 PM)
After market: 31.01 -0.25 (-0.8%)31.26
-0.07 (-0.22%)
The current stock price of RPRX is 31.26 USD. In the past month the price increased by 20.98%. In the past year, price increased by 6.84%.
RPRX Latest News, Press Releases and Analysis
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue...
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2024...
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.
Walgreens Boots Alliance, Aurora Innovation And Delta Air Lines Are Among Top Large Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?
Top performers in last week's stock market: Walgreens, Constellation Energy, FTAI Aviation, TD SYNNEX, Aurora Innovation, Royalty Pharma, Micron, Delta Air Lines, Intra-Cellular Therapies, United Airlines.
RPRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 81.23 | 784.20B | ||
| JNJ | JOHNSON & JOHNSON | 15.36 | 369.55B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 28.01 | 366.85B | ||
| MRK | MERCK & CO. INC. | 11.88 | 229.54B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.1 | 213.85B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.32 | 210.86B | ||
| PFE | PFIZER INC | 8.32 | 146.61B | ||
| SNY | SANOFI-ADR | 13.51 | 134.13B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 50.53 | 119.91B | ||
| ZTS | ZOETIS INC | 29.9 | 77.71B | ||
| GSK | GSK PLC-SPON ADR | 8.42 | 71.08B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 30.98 | 42.23B |
Related stock screener links
About RPRX
Company Profile
Royalty Pharma Plc provides drug development services. The company is headquartered in New York City, New York and currently employs 89 full-time employees. The company went IPO on 2020-06-16. The firm collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
Company Info
ROYALTY PHARMA PLC- CL A
110 East 59th Street
New York City NEW YORK 10022 US
CEO: Pablo Legorreta
Employees: 89
Company Website: https://www.royaltypharma.com/
Investor Relations: https://www.royaltypharma.com/investors
Phone: 12128830200
RPRX FAQ
What is the stock price of RPRX?
The current stock price of RPRX is 31.26 USD.
What is the symbol for ROYALTY PHARMA PLC- CL A stock?
The exchange symbol of ROYALTY PHARMA PLC- CL A is RPRX and it is listed on the Nasdaq exchange.
On which exchange is RPRX stock listed?
RPRX stock is listed on the Nasdaq exchange.
Is RPRX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for RPRX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of RPRX.
Does RPRX stock pay dividends?
RPRX has a dividend yield of 2.79%. The yearly dividend amount is currently 0.81.
When does RPRX stock report earnings?
RPRX will report earnings on 2025-02-11, after the market close.
What is the Price/Earnings (PE) ratio of RPRX?
The PE ratio for RPRX is 7.62. This is based on the reported non-GAAP earnings per share of 4.1 and the current share price of 31.26 USD.
What is the Short Interest ratio of RPRX stock?
The outstanding short interest for RPRX is 4.37% of its float.
RPRX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to RPRX. When comparing the yearly performance of all stocks, RPRX is one of the better performing stocks in the market, outperforming 77.93% of all stocks.
RPRX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to RPRX. While RPRX belongs to the best of the industry regarding profitability, there are concerns on its financial health.
RPRX Financial Highlights
Over the last trailing twelve months RPRX reported a non-GAAP Earnings per Share(EPS) of 4.1. The EPS increased by -14.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 50.53% | ||
| ROA | 6.35% | ||
| ROE | 16.67% | ||
| Debt/Equity | 0.96 |
RPRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 81% to RPRX. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of -7.59% and a revenue growth -5.27% for RPRX